Nexalin Technology received a notice from Nasdaq granting continued listing subject to conditions. The company must demonstrate compliance with the minimum bid price requirement by September 28, 2026, and meet the $2,500,000 stockholders' equity requirement by January 4, 2027. Additionally, it must maintain a closing bid price of at least $1.00 for 20 consecutive trading sessions. Failure to comply may result in delisting from Nasdaq. Nexalin Technology operates in the medical device industry, developing neuromodulation therapies.
